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Studies by Kunkel and co-workers (I-4) on human monoclonal rheumatoid 
factors (RF)  1 spontaneously arising in patients with Waldenstrom's macroglobu- 
linemia (5, 6) have greatly advanced our knowledge of the fine characteristics of 
these important anti-7-globulin autoantibodies. For experimental purposes, avail- 
ability of murine  monoclonal  RF will further expand our ability to assess the 
biologic significance of these autoantibodies in health and disease. 
Recently, we observed that mice of the MRL/Mp-lpr/lpr (MRL/I) substrain, in 
addition to lupus-like syndrome and massive T  cell proliferation caused by the 
lpr gene, develop an arthritic process very similar serologically and histologically 
to human rheumatoid arthritis (RA) (7, 8). Both IgM and IgGRF are detectable 
in their sera  (8,  9) as well as  IgG-IgGRF (9)  and  IgGRF-anti-DNA complexes 
(10). 
The availability of this murine substrain has prompted us to initiate studies on 
the genetics, fine specificities, and biologic roles of RF in their arthritic process. 
As  a  first  step,  we  derived  several  hybrids  between  unmanipulated  MRL/I 
splenocytes and myeloma cells that secreted monoclonal IgMRF (mIgMRF). This 
report details the IgG subclass, allotypic, IgG domain, and speciesspecificities of 
these monoclonal autoantibodies. 
Materials  and  Methods 
Mice.  MRL/1 mice (7,  11) were bred and maintained in our colony. The derivation, 
histologic, and serologic characteristics of this autoimmune substrain of mice have been 
detailed elsewhere (12). 
Cell Fusion.  Plasmacytomas of BALB/c origin used for the cell fusions included initially 
the hypoxanthine, aminopterin, thymidine (HAT)-sensitive cell line P3-X63-Ag8 express- 
ing immunoglobulin of the chain composition ~, 1 and K  and, when it became available, its 
variant P3-X63-Ag8.653  line (13).  The variant line has lost immunoglobulin expression 
entirely and does not synthesize -/1 or K  chains of X63 origin upon fusion with antibody- 
forming cells. For cell fusion, we used a modification of the technique described by Kohler 
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and Milstein (14). Briefly, splenocytes from unmanipulated 3.5-mo-old IgMRF-positive, 
MRL/1 mice were mixed with myeloma cells  (10:1  ratio;  1 x  l0  s spleen cells/1  x  107 
myeloma cells)  and a  35%  final concentration of polyethyleneglycol (PEG  1000; J.  T. 
Baker Chemical Co., Phillipsburg, NJ).  After fusion, the cell suspension was mixed with 
500 ml of selective HAT-Dulbecco's minimum essential medium (DMEM) supplemented 
with  10%  fetal bovine serum, glutamine, antibiotics, nonessential amino acids, sodium 
pyruvate, and 4.5 g glucose/liter that contained 2 x  106 fresh BALB/c thymocytes/ml. 
Subsequently, the cell suspension was distributed in 96-well tissue culture clusters with 
flat-bottomed wells (3596; Costar, Cambridge, MA). Cultures were placed in humidified 
37°C,  5% CO~ incubators and fed after approximately 8 and  14 d  with HAT-DMEM 
containing 5 x  106/ml  fresh BALB/c thymocytes. Propagation of hybridomas and sub- 
cloning at limiting dilutions were performed as described (15). 
Radioimmunoassayfor RFActivity.  The assay for IgMRF has been described (10). Briefly, 
polypropylene wells (Dynatech Laboratories, Inc., Alexandria, VA) were coated by desic- 
cation with  50 #1 of a  40 ug/ml polyclonal murine  IgG or 40 #g/ml of an equimolar 
mixture of all  murine myeloma IgG subclasses  (IgG1, IgG2a,  IgG2b, IgG3) in borate- 
buffered saline (BBS), pH 8.4. After appropriate washes and coating with 200 #1 of BBS 
containing 2% bovine serum albumin (BSA)-0.05% Tween 80, the wells were incubated 
overnight at 4°C with 50 #l of appropriately diluted test material. Washed wells were 
then incubated (4 h, 4°C) with 50 #l of affinity-purified ~SI-labeled (16) F(ab')2 goat anti- 
murine #-specific antibody (200  #g/ml  BBS-BSA-Tween 80).  Bound radioactivity was 
counted after a last series of five washes  in BBS and specific counts were calculated by 
subtracting the counts per min associated with wells incubated with control medium. The 
anti-# serum was  made by immunizing a  goat with MOPC-104E myeloma (#,X; Litton 
Bionetics Inc., Kensington, MD) and subsequent affinity purification on a Sepharose 4B- 
TEPC-183 (#,K; Litton Bionetics Inc.) column. The specifically bound counts of anti-# 
were referred to a standard curve made by using wells coated with unlabeled anti-# as the 
first reagent, TEPC-183 (#,K) myeloma diluted in BBS-BSA-Tween 80 at concentrations 
ranging from 200 to 0.4 #g/ml as the middle reagent, and ~25I-anti-# as the final reagent. 
Iglsotypes and lgG Subclasses.  Mouse IgM (TEPC-183), IgA (TEPC-15), IgG1 (MOPC- 
21), IgG2a (UPC10,  RPC5),  IgG2b (MOPC-195), and  IgG3 (J606) myelomas were all 
purchased from Litton Bionetics Inc., whereas murine IgE antidinitrophenyl monoclonal 
antibody was a gift from Dr. F. T. Liu, Medical Biology Institute, LaJolla, CA. Polyclonal 
IgG of murine, bovine, rabbit, rat, goat, and human origin were all purchased from Miles 
Laboratories, Elkhart, IN. Human myeloma IgG subclasses (IgG1, IgG2, IgG3, IgG4) of 
kappa  or  lambda  light  chains  and  of known  Gm  allotype  composition, and  rat  IgG 
subclasses (IgG1, IgG2a, IgG2b, IgG2c) were all a generous gift from Dr. H. Spiegelberg, 
Scripps Clinic and Research Foundation. Polyclonal murine IgG2a (Igh-1) of a, b, c, d, e, 
or j  allotypes were purified from sera of pertinent murine strains (17) by absorption on 
staphylococcal protein A-Sepharose CL-4B columns (Pharmacia Fine Chemicals, Uppsala, 
Sweden)  and  subsequent  elution  with  0.1  M  citrate/phosphate  buffer  gradient,  pH 
3.0-8.0, as described (18). The above proteins were used either as substrates or inhibitors 
in the RF radioimmunoassay. 
Aggregation of Immunoglobulins.  The  various  murine  myeloma  IgG  subclasses  and 
homologous  and  heterologous polyclonal  IgG  were  dissolved  in  BBS,  pH  8.4,  at  a 
concentration of 1 mg/ml. They were then heated (63°C or higher) until they became 
opalescent. The binding of selected mIgMRF to wells coated with an equimolar mixture 
of murine IgG subclasses  (40 #g/ml) was measured in the presence of various concentra- 
tions of inhibitor heat-aggregated IgG diluted in  BBS-BSA-Tween 80.  mIgMRF  were 
diluted to 50% of their maximal binding capacity before testing. 
Fab and Fc Fragments.  Murine  Fab and  Fc fragments were prepared as  follows.  A 
mixture of polyclonal IgG isolated from BALB/c serum and myeloma IgG2a (UPC-]0) 
was digested with papain (Worthington Biochemical Co., Freehold, N  J) at a 100:1 substrate 
to enzyme ratio at  37°C  for  1 h  in  0.15  M  phosphate-buffered saline (PBS),  pH  7.0, 
containing 0.002 M EDTA-tetrasodium salt (J. T. Baker Chemical Co.) and 0.02 M L- 
cysteine (Sigma Chemical Co., St. Louis, MO). The reaction was stopped by the addition THI~OFILOPOULOfi ET AL,  903 
of a slight excess of iodoacetamide.  Subsequently, the sample was dialyzed against PBS 
and  chromatographed on  a  Sephadex  G-100 (Pharmacia  Fine  Chemical) column  to 
separate undigested IgG from Fab and Fc fragments. The Fab- and Fc-containing material 
was then concentrated and passed through a Sepharose CL-4B-staphyiococcal  protein A 
column.  The  effluent and  the  0.1  M citrate  buffer (pH  3.5) eluate of this  column, 
containing Fab and Fc, respectively, were dialyzed against PBS, concentrated, and used 
at 10 #g/ml as substrates in the IgMRF radioimmunoassay. 
Human Fc (CH2-CH3 domains, residues 230-446) was obtained  as above by papain 
digestion of a myeloma, IgG1, X  (Gmf), except that digestion lasted 18 h instead of the 1 
h used for murine IgG2a. Human pFc' (CH3 domain, residues 335-446)  was obtained 
by plasmin (Sigma Chemical Co.) digestion of the above myeloma protein and subsequent 
chromatographies as detailed elsewhere (19, 20) so as to separate the large Fabc fragment 
that contains all but the terminal CH3 domain from the small molecular weight fragment 
consisting of the free CH3 domain. 
Staphylococcal  Protein A.  Protein A purchased from Sigma Chemical Co. as lyophilized 
powder was dissolved in PBS and used to localize the Fc region that mlgMRF recognized. 
Microtiter  wells were coated with the murine myeloma 19001, reacted  (40C, overnight) 
with an excess of protein  A  (250 #g/ml BBS), then washed and incubated  with the 
mlgMRF previously diluted to 50% binding capacity. After incubation, wells were washed, 
and  bound  IgM  was quantitated with  radioiodinated anti-#  as  described  for the  RF 
radioimmunoassay.  Controls  included  wells coated with  IgG and then incubated  with 
mlgMRF in the absence of protein A, and wells coated with IgG and then sequentially 
incubated with mlgMRF, washed, and finally reacted with ~5I-labeled protein A. 
Human Clq.  Human Clq was prepared as detailed  elsewhere (21). It was used for 
inhibition  studies  in  which selected  mlgMRF (diluted  to  50%  binding  capacity), the 
substrate mouse IgG, or both were preincubated with an excess amount of Clq and then 
checked for their ability to interact with each other as assessed by the RF radioimmu- 
noassay. 
Cross-reactions of mlgMRF with Non-lgG Molecules.  Cross-reactions of mlgMRF with 
mouse kidney nuclei, single-stranded DNA (ssDNA), and double-stranded  DNA (dsDNA) 
were assessed as described (7). Reactivity with total calf thymus histones was determined 
by using an enzyme-linked immunosorbent assay (ELISA) modified from a solid-phase 
test described by Rubin et al. (22). Binding to chick collagen II was checked by the solid- 
phase ELISA procedure of Stuart et al. (23). Binding to a synthetic pentapeptide  (L-AIa- 
D-GIu-L-Lys-D-Ala-o-Ala; kindly prepared by Dr.  R.  Houghten, Scripps Clinic and Re- 
search Foundation), which is identical with that in the peptidoglycan of streptococci (24), 
was assessed by inhibition radioimmunoassays in which binding of mlgMRF to substrate 
Ig was assessed in the presence of increasing amounts of the peptide (500-8 #g/ml). 
Results 
Murine lgG Subclass and Species Specificity of Serum Polyclonal lgMRF.  Before 
fusing MRL/1 splenocytes with myeloma cells to develop monoclonal autoanti- 
bodies,  we  randomly selected  20  MRL/i  female  mice,  3-4  mo  of age,  and 
checked their sera  for levels and specificities of polyclonal IgMRF for murine 
IgG subclasses and heterologous IgG (Table I). All sera tested contained signifi- 
cantly elevated amounts of IgMRF compared with sera of three normal control 
strains. Serum polyclonal IgMRF reacted with all murine IgG subclasses, but the 
degree of reactivity varied depending on the substrate subclass;  the majority of 
the sera (19  out of 20) reacted most strongly with mouse IgG2a. In regard to 
heterologous IgG, extensive cross-reactions with human, cow, rat,  rabbit, and 
goat IgG were noted. 
Hybridomas Secreting mlgMRF.  Four  hybridizations  were  performed  with 
spleen cells from individual, unmanipulated 3.5-too-old MRL/I mice shown to 904  MURINE  MONOCLONAL  IgM  RHEUMATOID  FACTORS 
TABLE  I 
Murine IgG Subclass and Heterologous IgG Specificity of Serum Polyclonal IgMRF* 
MRL/I  Mye-  Murine IgG subclasses  Heterologous IgG 
serum  loma 
No.  pool  IgG1  IgG2a  IgG2b  lgG3  Human  Cow  Rat  Rabbit  Goat 
tag IgMRF/ml serum 
1  30.6  10.1  41.4  5.1  11.3  4.1  5.3  7.7  3.2  4.2 
2  19.9  9.3  23.1  6.2  15.2  15.3  5.4  9.8  3.6  2.7 
3  69.0  12.1  77.4  8.2  11.2  10.4  4.5  13.9  8.2  6.3 
4  25.6  21.6  19.5  15.2  22.9  11.0  8.1  16.4  11.3  10.1 
5  61.3  17.6  69.6  17.3  32.5  14.6  5.4  17.7  11.8  4.8 
6  18.7  6.1  20.8  7.7  12.9  5.5  4.7  5.2  4.9  4.7 
7  80.2  88.7  69.4  24.9  37.1  10.5  16.5  82.9  9.1  10.0 
8  45.7  8.7  22.5  49.6  22.2  11.9  7.9  10.4  8.0  8.6 
9  51.0  37.5  59.2  24.6  27.0  16.4  14.0  36.5  14.2  17.6 
10  20.7  10.4  13.7  13.7  13.9  10.0  6.8  9.8  8.6  2.0 
11  14.9  8.5  15.0  7.6  8.3  8.5  5.7  4.1  3.9  7.3 
12  28.3  7.0  25.2  14.5  18.4  5.1  5.7  3.0  3.5  5.0 
13  55.1  17.8  79.4  5.2  14.5  4.3  3.7  6.0  5.8  4.9 
14  28.9  16.4  45.8  5.2  7.8  5.1  3.9  4.9  2.5  4.7 
15  27.4  34.9  14.2  18.1  11.8  9.0  16.4  34.9  7.6  12.3 
16  17.5  11.7  53.4  5.4  17.3  8.6  3.3  14.7  13.2  3.1 
17  49.8  21.0  22.9  47.3  35.8  17.1  12.4  20.1  13.3  11.8 
18  25.8  10.8  27.4  14.1  9.4  9.7  5.9  8.6  5.8  8.7 
19  30.7  19.8  17.4  46.0  21.5  14.9  10.I  13.4  34.5  9.0 
20  18.8  26.7  4.9  4.6  2.6  3.0  5.1  8.8  1.6  4.3 
Normal serum 
pools 
C3H/St  3.9  0.3  0.4  0.7  0.4  0.5  0.0  0.0  0.2  0.0 
C57BL/6  4.2  0.4  0.5  0.4  0.7  0.3  0.0  0.0  0.0  0.0 
BALB/c  4.6  0.4  0.7  1.4  0.9  0.7  0.3  0.0  0.3  0.2 
* Microtiter wells were coated with 40 #g/ml of pooled murine myeloma immunoglobulins (all four 
subclasses), 10 #g/ml of individual murine myeloma subclasses, or 40 #g/ml of heterologous IgG. 
contain  high  levels of serum  IgMRF  of broad  specificity (mice  5,  7,  9,  and  17, 
listed in Table  I). At the completion of each hybridization the cells were cloned 
by  limiting  dilution  in  "~2,000  microtiter  wells.  After  2.5-3.5  wk,  hybrids 
developed  in  305,  218,  633,  and  567  wells,  respectively,  for  a  total  of  1,723 
hybrids in the four fusions.  Of these, 4,  3, 4, and  12 clones or 1.3,  1.4,  0.6, and 
2.1%,  respectively,  secreted  IgMRF.  Positive  clones  from  these  experiments, 
termed  RF1  through  RF23,  were  found  to  secrete  considerable  amounts  of 
autoantibody  at the time of first testing (Table II). Poisson distribution analysis 
indicated  that  <1%  of the  postive  wells could  have  contained  more  than  one 
IgM  anti-IgG-secreting  clone.  Nevertheless,  to  ensure  that  our  mathematical 
assumption  was correct,  we subcloned seven  clones and  found  that all secreted 
IgMRF  in amounts  similar to those of the parental clones. Sequential analysis of 
all positive clones  over a  period  of at  least 6  mo  has  shown  stable amounts  of 
autoantibody  production. 
Isotype Spec~cities of the mlgMRF.  Classically, RF bind to IgG and very rarely 
to other  immunoglobulin  isotypes (reviewed in  reference  25).  Affinity-purified 
IgM  from  five  of the  most  active  clones  were  radioiodinated  and  their  direct THEOFILOPOULOS  ET  AL. 
TABLE  II 
Hybridomas Secreting  mlgMRF* 
Clone No.  IgMRF  Clone No.  mlgMRF 
#g/ml  #g/ml 
RF1  4.02  RF13  4.80 
RF2  48.61  RF14  0.16 
RF3  4.30  RF15  0.32 
RF4  0.72  RF16  5.36 
RF5  1.10  RF17  2.12 
RF6  1.48  RF18  2.44 
RF7  5.98  RF19  3.71 
RF8  4.08  RF20  0.32 
RF9  11.40  RF21  1.79 
RF10  1.70  RF22  1.67 
RF11  0.20  RF23  21.42 
RF12  1.12 
* Tested on an equimolar pool of murine myeloma IgG1, IgG2a, IgG2b, 
and IgG3 at a  total concentration of 40 #g/ml.  Numbers indicate #g 
mIgMRF/ml culture supernatant. The first 7 positive clones were de- 
rived from  the two  fusions with the secretor  myeloma  line, and  the 
remaining 16 were derived from the fusions with the nonsecretor line. 
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binding  to  murine  IgG  and  IgM  isotypes  was  ascertained.  Additionally,  all 
mIgMRF were checked for binding to IgA and IgE substrate in the same fashion 
as assessed for binding to IgG substrate using radioiodinated anti-t~ as the final 
reagent.  All  monoclonal autoantibodies  showed significant binding to murine 
IgG but not to IgM, IgA, or IgE (data not shown). 
IgG Subclass Specificities of the mlgMRF.  The IgG subclass specificities of the 
23 monoclonals are listed in Table III. Eight clonotypes were identified, and the 
majority of the monoclonals reacted either exclusively with IgG2a (seven clones) 
or with all IgG subclasses equivalently (five clones). Of the remaining monoclo- 
nals, three bound to IgG2b only, four to IgG1 :IgG2a:IgG3, one to IgG2a:IgG3, 
one to IgGl:IgG3, one to IgGl:IgG2a, and one to IgG2b:IgG3.  No clone that 
reacted exclusively with IgG1 or IgG3 was identified, although clonesRF8 and 
RF2  bound  much better  to  these  two  subclasses,  respectively,  than  to other 
subclasses. 
Similar specificity patterns were observed in competition experiments with a 
pool  of  the  four  murine  IgG  subclasses  used  as  a  substrate  and  individual 
aggregated  IgG subclasses as inhibitors.  Representative inhibition experiments 
with clone RF8 are depicted in Fig. 1. 
Allotypic Specificit#s  ofAnti-IgG2a mlgMRF.  Six mIgMRF that bound to IgG2a 
only were tested for their allotypic specificities against polyclonal IgG2a isolated 
from the sera of mice expressing Igh-1 allotype of the a, b, c, d, e, or j  alleles 
(Table IV).  Four monoclonal autoantibodies (RF9, RF13,  RF17, RF23) bound 
to IgG2a  of the a,  c, and e  alleles but not those of the b,  d, and j  alleles.  In 
contrast,  two of these  monoclonais showed additional  specificities:  RF14  also 
reacted with the b allotype and RF22 reacted with all substrate allotypes. It was 
noteworthy that Igh-1 antigenic specificities represented in the reactive allotypes 
were  also  represented  in  the  nonreactive  allotypes and  vice  versa.  The  only 906  MURINE  MONOCLONAL  lgM  RHEUMATOID  FACTORS 
TABLE  III 
Spec~cities of mlgMRF  for Mouse IgG Subclasses* 
Clone  No.  IgG1  IgG2a  IgG2b  IgG3 
ug mlgMRF/ml 
RF6  --*  1.44  --  -- 
RF9  --  20.60  --  -- 
RF13  --  5,53  --  -- 
RF14  --  0.85  --  -- 
RF17  --  2.15  --  -- 
RF22  --  2.25  --  -- 
RF23  --  26.45  --  -- 
RF7  --  --  14.48  -- 
RFIO  --  --  1.78  -- 
RFll  --  --  0,2~  -- 
RF4  0.76  0.55  0,56  0.94 
RF5  0.82  0.71  0.49  0.70 
RF 18  4.07  2.23  1.49  8.66 
RF20  0.45  0.25  0.37  0.50 
RF21  2.66  3,50  3.19  4.62 
RF2  0.66  1,05  --  42,36 
RF3  1.42  4.43  --  4.06 
RFI6  4,42  4.25  --  1.31 
RF19  4,57  2,55  --  0.71 
RF1  --  8.43  --  1.59 
RF8  32.30  --  --  0.72 
RF12  1.02  0.81  --  -- 
RF15  --  --  0,2  0.22 
*  Microtiter  wells were coated  with individual routine  myeloma  IgG sub. 
strates at a  concentration  of 10 ~g/ml.  Numbers  indicate ~g IgMRF/ml 
culture supernatant. 
¢ Binding equal to background  levels. 
IoG2b 
I09~ I  ~  n_  .~  ~IgG2a 
so,i 
'°1  ,  ,  .t  1,0  10  100  1000 
Concentretloa  of Competing  Protein  (/,q~ml) 
FIGURE  1.  Murine  IgG subclass specificity of mIgMRF.  The  binding of monoclonal  antibody 
RF8 to a  substrate pool of four murine  IgG subclasses was assessed in the presence of various 
concentrations  of heat-aggregated  lgG1,  IgG2a,  IgG2b,  or lgG3. THEOFILOPOULOS  ET  AL. 
TABLE  IV 
Allotypic Specificities  of Anti-IgG  2a mlgMRF 
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Source of IgG2a*  Igh-1 allele* 
BALB/c  a 
Igh- 1 antigenic* specificities 
1, 6, 7, 8, 26, 28, 29, 30 
C57BL/6  b  2, 27, 29 
DBA/2J  c  3, 8, 29 
AKR]J  d  4, 6, 7, 8, 26, 29 
NZB  e  4, 6, 7, 8, 26, 28, 29, 30 
CBA/CaJ  j  I, 6, 7, 8, 28, 29, 30 
Clone No.  mlgMRF 
vc/ml 
RF9  11.73 
RF13  3.23 
RF14  0.5 
RFI7  0.18 
RF22  1.28 
RF23  13.95 
RF9  (__)0 
RF13  (--) 
RF14  0.3 
RF17 
RF22  0.3 
RF23 
RF9  25.92 
RF13  5.66 
RF14  0.25 
RF17  0.11 
RF22  2.47 
RF23  10.09 
RF9  (--) 
RFI3  (--) 
RF14 
RF17 
RF22  0.35 
RF23 
RF9  24.00 
RF13  1.55 
RF14  0.17 
RF17  0.48 
RF22  2.12 
RF23  11.34 
RF9  (--) 
RF13 
RFI4 
RF17 
RF22  0.41 
RF23 
* Microtiter wells were coated with the various IgG2a at a concentration of 10 gg/ml. 
* See reference 17. 
§ Indicates no binding above background level; parenthesis denote very weak binding (< 10 ng/ml). 
exception was clone RF22,  which had broad reactivity with all allotypes that 
shared the antigenic specificity 1.29. 
Binding ofmlgMRF to Heterologous  IgG.  The binding of the mlgMRF to human, 
cow, goat, rat, or rabbit IgG is shown in Table V. Four clonotypes were identified. 
11 mlgMRF reacted only with homologous but not heterologous IgG, 5 with all 
heterologous IgG; 6 cross-reacted only with rat IgG, and 1 with all heterologous 
IgG except human IgG. Monoclonals with exclusively anti-mouse !gG2a or anti- 
mouse IgG2b activity did not cross-react with heteroiogous IgG. The data on 
heterologous IgG cross-reactions were confirmed by competition experiments 908  MURINE  MONOCLONAL  IgM  RHEUMATOID  FACTORS 
TABLE  V 
Binding of mlgMRF to Heterologous IgG* 
Clone No. 
Levels of  Murine IgG 
IgMRF with  subclass 
mouse IgG as  specificity 
substrate 
Heterologous IgG 
Human  Cow  Goat  Rat  Rabbit 
RF6  1.48  IgG2a  --* 
RF9  11.40 
RF13  4.80  I 
RFI4  0.16 
RF17  0.12 
RF22  1.67 
RF23  21.42 
I 
i 
B 
i 
B 
m 
I 
m 
I 
m 
m 
RF7  5.98 
RF10  1.70 
RF11  0.20 
IgG2b 
m 
I 
B 
i 
B 
h 
i 
i 
m 
RF4  0.72  IgGl, 2a, 2b, 3  1.28  0.22  0.37  0.23 
RF5  1.10  1.70  0.70  0.50  0.49 
RF18  2.44  4.13  4.29  7.90  4.32 
RF20  0.32  0.20  0.56  0.36  0.27 
RF21  1.79  1.15  3.46  2.66  2.10 
0.42 
0.18 
5.90 
0.29 
1.53 
RF2  48.61  IgG1, 2a, 3  --  2.33  1.07  32.09 
RF3  4.30  --  --  --  1.67 
RF16  5.36  --  --  --  0.57 
RF19  3.71  I  __  --  0.27 
0.51 
RF1  4.02  IgG2a, 3  --  --  --  1.18 
RF8  4.08  IgG1, 3  i  __  --  8.66 
RF12  1.12  IgG1, 2a  .... 
RF15  0.32  IgG2b, 3  --  --  --  0.18 
* Microtiter wells were coated with pooled murine myeloma lgG or heterologous polyclonal  lgG at 
a concentration of 40 #g]ml. Numbers indicate #g mIgMRF/ml culture supernatants. 
* No binding above background levels. 
with murine polyclonal IgG as a substrate and heterologous heat-aggregated IgG 
as competitors. Representative inhibition experiments with RF8 are depicted in 
Fig.  2.  Five  monoclonals cross-reactive  with human  and rat polyclonal  IgG (as 
well as  IgG  from  other  species)  and  one  monoclonai  cross-reactive  only  with 
polyclonal rat IgG were tested for human and rat IgG subclass and human IgG 
ailotype specificity (Table VI). Despite some variability in the degree of binding, 
the five human and rat IgG cross-reacting monoclonals bound to all human IgG 
subclasses,  albeit in most instances to a lesser extent to IgG1  than to the other 
human subclasses, irrespective of their allotypes, and to all rat IgG subclasses.  In 
contrast,  the rat IgG cross-reacting monoclonal bound to rat IgG1  and  IgG2a 
but not to rat IgG2b and IgG2c. 
Ig Subfragment Specificity of mlgMRF.  All  monoclonals  were  tested  for  IgG 
subfragment specificity using as substrates Fab or Fc derived from BALB/c IgG. 
With  the exception of one monoclonai,  only the  Fc, and  not the Fab,  elicited 
binding  (Table  VII),  thus  affirming  these  monoclonals'  characterization  as THEOFILOPOULOS  ET  AL. 
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FIGURE  2.  Heterologous  IgGspecificity  of mlgMRF.  The  binding  of monoclonal  antibody 
RF8 to substrate polyclonal murine  IgG was measured  in the presence of various concentrations 
of heat-aggregated  polyclonal IgG of homologous  and heterologous  (goat, rabbit, cow, human, 
rat) origin. 
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TABLE  VI 
Binding of mlgMRF to Human and Rat IgG Subclasses and to Human IgG Allotypes 
Clone  Mouse IgG  Human IgG subclasses (allotypes)* 
No.  subclass  lgGI  IgGl  IgGl  lgG2  lgG2  IgG3  IgG3  lgG4  lgG4 
specificity  (Gm  a)  (Gm  f)  (Gm  r)  (Gm,.)  (Gin  n-)  (Gm  b)  (Gml)  (Gm  I)  (Gin  b) 
Rat lgG subclasses  II 
IgGl  lgG2a  IgG2b  lgG2c 
RF4  IgG1, 2a, 2b, 3  0.27  0.12  1.05  1.11  0.2  0.37  0.33  1.22  6.94  0.80  0.40  0.80  0.10 
RF5  0.26  0.47  0.55  4.76  15.07  2.51  3.60  4.12  10.04  0.60  __!  0.60  0.20 
RF18  1.99  0.68  0.76  3.39  0.48  5.29  5.93  9.75  9.50  3.27  0.76  2.63  2.19 
RF20  0.63  0.60  0.68  0.99  0.64  0.91  1.01  1.0~  1.21  ND  !  ND  ND  ND 
RF21  4.35  5.65  5.32  4.82  3.46  4.00  5.93  7.01  7.83  0.50  0.39  0.40  0.53 
RF8  lgGl, 3  .........  3.16  0.90  -- 
* Each human myeloma IgG subclass, derived from different individuals,  was used as a substrate at a concentration of 10 #g/m]. Numbers 
indicate t~g mlgMRF/ml culture supernatant. 
1: Polyclonal rat lgG subclasses. 
J Binding equal to background  levels. 
II Not determined. 
mIgMRF. The exception was clone RF15,  which bound to both substrates but 
better to Fc than to Fab. The amounts of IgMRF in each monoclonal, as defined 
by binding to the myeloma pool versus the isolated Fc, did not match. In most 
instances, Fc promoted better binding than did the IgG pool, perhaps because 
of a higher availability  of Fc sites in the former. However, some of the mono- 
clonals registered higher values for the pool of four IgG subclasses than for the 
Fc  substrate,  apparently reflecting the  poorer representation of certain  IgG 
subclasses, such as IgG3, in the Fc preparation (derived from IgG2a and poly- 
clonal  IgG)  than  in  the  equimolar  pool  of all  four  murine  IgG  subclasses. 
Examples are clone RF2, with primarily an IgG3 specificity, and clone RF8, with 
primarily an  IgG1  specificity (Table III), both of which reacted best with the 
pool presumably more abundant in both subclasses. 
Attempts to Define the Fc Antigenic Determinants  for mlgMRF.  The globular head 
of a Clq molecule binds to the CH2 domain of antibody (26,  27).  Moreover, 
protein A, a constituent of the cell wall of Staphylococcus aureus, binds to the Fc 
sites on antibody molecules of all murine IgG subclasses, but does not interfere 
with complement binding (28). Interaction with an excess of human C lq did not 
inhibit binding by any of the mIgMRF to substrate IgG (data not shown).  Nor 910  MURINE  MONOCLONAL  IgM  RHEUMATOID  FACTORS 
TABLE  VII 
Spec~city of mIgMRF for IgG Fc* 
Clone No.  Myeloma lgG  Fab  Fc 
pool 
RF1  4.02  --*  >19.47 
RF2  48.61  --  1.10 
RF3  4.30  --  24.05 
RF4  0.72  --  0.27 
RF5  1.10  --  0.26 
RF6  1.48  --  0.26 
RF7  5.98  --  1.35 
RF8  4.08  --  1.34 
RF9  11.40  --  32.12 
RF10  1.70  --  0.16 
RF 11  0.20  --  0.06 
RF12  1.12  --  4.08 
RF13  4.80  --  6.85 
RF14  0.16  --  0.25 
RF15  0.32  0.06  0.09 
RF16  5.36  --  10.44 
RF17  2.12  --  1.13 
RF18  2.44  --  9.64 
RFI9  3.71  --  9.11 
RF20  0.32  --  1.78 
RF21  1.79  --  7.24 
RF22  1.67  --  6.46 
RF23  21.42  --  >44.55 
* Microtiter wells were coated either with a pool of the four IgG subclasses 
(40  t~g/ml),  Fab (10  ~g/ml), or Fc (10  ug/ml).  Numbers indicate ~g 
IgMRF/ml culture supernatant. 
* Binding equal to background values. 
did C lq inhibit this reaction when preincubated  with both the mlgMRF  and the 
substrate  IgG.  Thus,  none  of our  mIgMRF  recognized antigenic determinants 
in or around  the Clq  binding site at the CH2  domain.  In contrast,  12  of the 23 
mIgMRF  were  strongly inhibited (>50%)  from  binding to substrate  IgG when 
protein  A  was  used as a  competitor  (Table  VIII).  Of the  remaining  1 1  mono- 
clonals,  1  (RF7) showed a  partial inhibition (38.4%)  whereas  10  were inhibited 
very weakly or not at all.  No consistent pattern  was observed  in  regard  to  the 
inhibitory ability of protein A  and any one murine  IgG subclass specificity of the 
mIgMRF.  We conclude that  over half of our  mIgMRF  recognize determinants 
localized at  the  IgG  CH2-CH3  junction  or at  sites distant to  the junction  that 
might  be  altered  or  hidden  via  conformational  changes  or  contact  with  the 
protein A. 
To determine  which of these two possibilities is more likely, we performed  the 
converse  experiment  where  the  IgG  substrate  was  first  incubated  with  the 
monoclonal autoantibodies and then with radioiodinated protein A. Under  these 
conditions the protein A  binding was similar to that seen in control wells where 
the substrate IgG had not been preincubated with the mIgMRF, i.e., no inhibition 
was  observed.  Thus,  we  conclude  that  the  actual  binding  site  for  this  type  of 
mIgMRF  is  not  localized at  the  CH2-CH3  junction  but  at  distant  sites  at  the THEOFILOPOULOS ET AL. 
TABLE VIII 
Inhibition of Binding of mlgMRF to Substrate IgG by Staphylococcal Protein A* 
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Murine IgG  Percent  Murine IgG  Percent 
Clone No.  subclass  Clone No.  specificity  inhibition*  subclass specificity  inhibition 
RF6  IgG~a  89.5  RF4  IgG1, 2a, 2b, 3  .17.1 
RF9  98.3  RF5  0.0 
RFI3  94.7  RF18  8.3 
RF 17  86.4  RF20  10.4 
RF22  94.5  RF21  11.7 
RF14  0.0 
RF23  0.2  RF2  IgG1, 2a, 3  98.9 
RF3  88.6 
RF16  92.7 
RF19  89.8 
RF10  IgG2b  78.2 
RFll  5.2 
RF7  38.4 
RF1  IgG2a, 3  97.3  RF8  IgGl, 3  4.7 
RF12  IgG1, 2a  92.6  RF15  lgG2b, 3  0.0 
* Each mlgMRF, diluted to 50% binding capacity, was incubated with substrate IgG (pool of the 
four murine  myelomas, 40 #g/ml) that  had previously been coated with protein  A. Following 
washings, the binding was assessed with radiolabeled anti-#. 
* Percent inhibition -~ [1 -  (binding in the presence of protein A [cpm])/(binding in the absence of 
protein A [cpm])] × 100. 
CH2 or CH3 domains that are simply unavailable because of shielding via close 
contact with the protein A  chains or because of conformational changes in the 
IgG molecule. 
Among the monoclonals not inhibited o r  weakly inhibitable by protein A were 
the five autoantibodies that  cross-reacted extensively with all  murine  IgG sub- 
classes and with heterologous IgG. To localize the antigenic determinant involved 
in the induction of this type of autoantibody, we examined their ability to interact 
with Fc (CH2-CH3) or pFc' (CH3 domain) of human IgG1. All five monoclonals 
bound equally well to the two substrates  (data not shown), strongly suggesting 
that the binding site for these monoclonals is at the CH3 domain. 
Cross-reactions of mlgMRF with Non-lgG Substances.  None of the  23  mIgMRF 
cross-reacted  with  dsDNA,  chick  collagen,  or  synthetic pentapeptide  L-AIa-o- 
GIu-L-Lys-D-Ala-D-Aia. However, five of the mIgMRF (clone RF7,  RF8,  RF18, 
RF20, RF21) cross-reacted with ssDNA and two of the mIgMRF (clone RF7 and 
RF 16) showed strong cross-reactions with total calf thymus histories and bound 
to mouse kidney nuclei. The detailed fine specificities of these six mIgMRF will 
be described in a separate report. 2 
Discussion 
This is the first report of mlgMRF derived from the polyclonal pool of IgMRF- 
producing cells that arise spontaneously in MRL/I mice. Others have used similar 
methods  to obtain  monoclonal autoantibodies  against  erythrocytes (29),  DNA 
2 Rubin, R. L., A. N. Theofilopoulos, E. M. Tan, and F. J. Dixon. Antihistone and anti-DNA 
activities of monoclonal rheumatoid factors produced by MRL/I mouse-derived hybridomas. Manu- 
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(30), RNA (31), and Sm (32) from spontaneous murine models of lupus. 
Spontaneously occurring monoclonal anti-y-globulins are frequently found in 
sera of patients with Waldenstrom's macroglobulinemia (5,  6).  Kunkel and co- 
workers (1-4)  were the first to divide such mRF into two main groups on the 
basis of their heavy and light chain variable region subgroups and cross-reacting 
idiotypes. Subsequently, these (33) and other investigators (34, 35) demonstrated 
share idiotypic determinants between certain of these mRF and some polyclonal 
RF associated with RA. Thus, these RF have proven extremely useful in defining 
the amino acid  composition and  the  biochemical and  idiotypic repertoires  of 
human anti-y-globulins,  but  their  quantities are  limited.  Other  mlgMRF (36) 
were  the  products  of myeloma  cells  fused  with  splenocytes  of  129/Sv  mice 
preinjected  with  lipopolysaccharide  (LPS),  a  polyclonal  B  cell  activator.  Still 
another mlgMRF originated from B cells of an individual with RA after in vitro 
stimulation with Epstein-Barr virus (37).  Although such mitogen-induced auto- 
antibodies and monoclonals therefrom are useful reagents, they may not repre- 
sent  naturally  occurring  and  disease-associated  autoantibodies.  For  example, 
spontaneously expressed RF in certain colonies of 129/Sv mice are IgA or IgM 
anti-IgG2a  Fc (38,  39).  In contrast,  mlgMRF from such animals injected with 
LPS were almost exclusively of the IgM anti-IgG 1 Fv type (36). Thus, for analysis 
of the fine epitopic specificities and of clonotypic and idiotypic characteristics of 
autoantibodies,  monoclonals derived from the pool of spontaneously autoanti- 
body-secreting cells in animals with the relevant disease  might be  superior to 
those induced by exogenous polyclonal stimuli. 
In  a  similar  fashion  to  what  has  been  described  for  human  RF  (40-42), 
polyclonal  RF  in  sera  of  MRL/I  mice  reacted  broadly  with  all  murine  IgG 
subclasses and heterologous IgG, but in most instances, reactivity was stronger 
with murine IgG2a.  Similarly, the majority of our mlgMRF had specificity for 
IgG2a,  exclusive  or  in  association  with  other  murine  IgG  subclasses.  Since 
immune complexes appear to play a  primary role in the induction of RF (43- 
45), one might suggest that the high expression ofanti-IgG2a RF in MRL/I mice 
is caused by a larger representation of IgG2a in the immune complexes that are 
abundantly present in sera of such mice. Indeed, most autoantibodies (anti-DNA, 
anti-gp70, anti-Sm) in these mice are predominantly or exclusively of the IgG2a 
subclass (46) 3 and the majority of their circulating immune complexes contain 
IgG2a as the antibody. If RF are indeed directed against antibodies complexed 
with antigen, they may act as enhancing antibodies similar to those described by 
Nemazee and Sato (47) that increase production of non-RF autoantibodies. 
All  our  monoclonals with  anti-IgG2a  or  anti-IgG2b activity  failed to cross- 
react  with  other  murine  IgG  subclasses  or  heterologous  IgG.  Similarly,  one 
mlgMRF  described  by  van  Snick  and  Coulie  (36)  that  exhibited  anti-IgG2a 
activity failed to cross-react,  unlike their many cross-reactive anti-IgG1  mRF. 
Moreover,  spontaneous  polyclonal  RF  of  129/Sv  mice were  exclusively anti- 
IgG2a without cross-reactivity with other murine IgG subclasses or heterologous 
IgG (38, 39). This lack of cross-reactivity by anti-IgG2a autoantibodies counters 
3 Slack, J.  H., L.  M. Hang, J.  Barkley, R.J.  Fulton, L.  D. Hoostelaere,  A. Robinson, and F. J. 
Dixon. The isotypic preferences of spontaneous B cell activators and the lgG subclasses of immune- 
complexed immunoglobulins  of systemic lupus erythematosus.  Manuscript submitted for publication. THEOFILOPOULOS  ET  AL.  913 
the extensive structural homologies (65%) among various murine IgG subclasses 
and between murine and human subclasses (48, 49). Thus, our mIgMRF of anti- 
IgG2a or anti-IgG2b type seem to be directed against amino acid sequences or 
conformational determinants that are exposed uniquely in the aggregated forms 
of these murine IgG subclasses.  Reviewing the sequence characteristics of the 
aligned CH2  and CH3  domains of the reactive IgG2a and,  for example, the 
nonreactive mouse IgG1 (50), one finds that these two subclasses differ at amino 
acid residue portions 229-235,  241-254,  and 287-294  of the CH2 and 357- 
372, 381-391, and 416-429 of the CH3 domain. Of these six portions, residues 
287-294,  357-372,  and particularly 416-429,  which are rich  in  hydrophilic 
amino acids (iysine, arginine, aspartic acid, and glutamic acid) are more likely to 
be exposed at the outer surface of the folded IgG2a  moleule and,  therefore, 
more likely to  stimulate  RF  production after their complexing with antigen. 
Obviously, antigenic determinants for the above mIgMRF cannot be defined 
accurately until the respective peptides have been synthesized and appropriately 
tested. 
When  we examined our anti-IgG2a  mIgMRF  for allotypic specificities,  we 
found that the majority of them reacted with a,  c, and e  but  not b,  d,  and j 
allotypes. Similarly, polyclonal RF of 129/Sv mice and mIgMRF from fused cells 
of LPS-injected 129/Sv mice were restricted in their Igh-1 allotypic specificities 
(36, 38). Gm (allotypic) genetic antigens of the human IgG constant homology 
regions of the heavy chains  are often involved  in  human  RF  reactions,  and 
several such  antigens  were first  identified  by  using anti-Gm  antibodies  from 
patients  with  RA  (51,  52).  Certain  allotypes  are  also  associated  with  some 
autoimmune diseases of humans, including systemic lupus  erythematosus and 
RA  (reviewed in  reference 53).  Moreover, a  gene  linked to  the  Igh-C  locus 
controls the levels and quality of RF production in some mice (54). In reviewing 
the known antigenic specificities of the allotypes used as substrates in our study, 
none can be singled out as the target determinant, since specificities in reactive 
allotypes also appear in the nonreactive allotypes and vice versa. On this basis, 
one can  speculate that  our anti-IgG2a  monoclonals react with  a  new,  as yet 
undefined, antigenic  specificity.  However,  the  known  atigenic  specificities of 
IgG2a allotypes have been defined with polyclonal homologous or heterologous 
antiallotypic antibodies.  Therefore, the monoclonal anti-IgG2a autoantibodies 
could react with a subregion of a known specificity that the polyclonal antiallo- 
typic serum does not distinguish. 
In contrast to the restricted anti-IgG2a and anti-IgG2b mIgMRF, monoclonal 
autoantibodies  reacting with  all  murine  IgG  subclasses  cross-reacted with  all 
heterologous IgG without preference for a given human IgG subclass or allotype. 
These results indicate that broadly cross-reacting anti-"r-globulins recognize an 
antigenic determinant that has been highly conserved phylogenetically. 
In direct binding assays, all but one of the monoclonal autoantibodies bound 
to the Fc but not to the Fab portion of mouse IgG, conclusively demonstrating 
that these monoclonals had the sine qua non qualities of RF. The one exception 
was monoclonal RF15, which bound to both Fab and Fc, suggesting the presence 
of a common antigenic determinant in Fab and Fc. In contrast to our mIgMRF 
derived from the natural  repertoire of the MRL/!  IgMRF,  48  mIgMRF from 914  MURINE MONOCLONAL IgM  RHEUMATOID FACTORS 
LPS-injected 129/Sv mice (36) did not bind to Fab or Fc, theoretically because 
these monocionals were directed against the Fv region of mouse IgG. This is an 
unusual characteristic for RF and contrasts with the specificity for Fc of sponta- 
neous polyclonal RF from 129/Sv mice described by the same authors (38, 39). 
These findings further support our contention that mitogen-induced autoanti- 
bodies may differ from natural autoantibodies in isotypic characteristics and also 
epitopic specificities. 
With Fc identified as the fragment against which our mIgMRF were directed, 
inhibition studies with protein A  and Clq were done to more precisely locate 
the antigenic determinants involved. The C 1  q binds via its globular heads to the 
CH2 domains of antibodies (26, 27) at the highly conserved amino acid sequences 
encompassed within residue 316-338  (55).  However, C 1  q did not inhibit inter- 
actions of any of the mIgMRF with substrate IgG, thus ruling out this site as a 
responsible antigenic determinant. This finding indicates that fixation of C 1  q by 
immune complexes does not interfere with RF binding or vice versa. Yet protein 
A,  which binds  to  Fc  but  does not  interfere with  complement binding  (28), 
inhibited the interactions of over one-half of our mIgMRF with the substrate 
IgG. The crystal structure of the complex between fragment B of protein A and 
Fc fragments indicates that protein A  binds at the CH2-CH3 junction (28,  56, 
57).  Thus,  the  antigenic sites  for  12  of the  23  mIgMRF  that  were  strongly 
inhibited by protein A could be placed at or very near the CH2-CH3 junction. 
However, in the converse experiment, binding of mIgMRF to substrate IgG did 
not inhibit subsequent binding of protein A to this substrate, indicating that the 
binding sites for RF and protein A  are not identical. Therefore, the antigenic 
sites for the RF are distant to the junction but become inaccessible as tertiary 
IgG folding patterns change after protein A  binds.  Alternatively, IgG Fc sites 
distant to the junction in both the CH2 and CH3 domains may become sterically 
blocked by the protruding chains of the bound protein A, as the crystallographic 
studies of Deisenhofer (57) have strongly suggested. These sites may include the 
antigenic determinants identified above on the basis of subclass specificity and 
structural differences between IgG subclasses, but their exact location on the Fc 
domains cannot be accurately defined at this time. In contrast, the antigenic site 
for mIgMRF weakly or not inhibited by protein A is at the CH3 domain. This 
group includes the five monoclonals that reacted broadly with all murine IgG 
subclasses and various heterologous IgG. That the site for these five monoclonals 
is at  the CH3  domain was  demonstrated by their equal binding to human Fc 
(CH2-CH3) and pFc' (CH3) pieces. 
Studies with human polyclonal RF have shown that some of them cross-react 
with the nucleosomal histone complex or ssDNA (58). Antihistone reactivity was 
also described with a Waldenstrom-derived mRF (59). We found that two of our 
mIgMRF exhibited cross-reactions with murine IgG subclasses and certain calf 
thymus bistones. Elution and inhibition studies to be reported  2 showed that the 
multiple  reactivities  of each  mIgMRF  were a  property  of a  single  antibody 
population.  Moreover, five mIgMRF reacted with IgG and ssDNA, and one of 
the five had additional reactivity with histones. The biologic significance of this 
type of cross-reaction and the relationship, if any, of the antigenic determinants 
involved in the activities of these peculiar autoantibodies remain unknown. THEOFILOPOULOS ET AL.  915 
Anticollagen autoantibodies have been described in RA (60) but possible cross- 
reactions of RF with collagen have not been examined. However, none of our 
mIgMRF reacted with chick collagen II. Finally, Bokisch et al. (24) described 7S 
RF-like antibodies of restricted molecular heterogeneity in  rabbit  immunized 
with streptococcal cell wall peptidoglycan. A defined pentapeptide sequence of 
peptidoglycan inhibited interactions of such antibodies with IgG Fc. Our studies 
failed to disclose any reactivity of the mIgMRF with the pentapeptide sequence 
of peptidoglycan, thus making it unlikely that MRL]l-associated RF form against 
such bacterial antigens that cross-react with IgG. Further studies of the mIgMRF 
that are derived from the natural repertoire of the MRL/I mice will allow us to 
better define their roles in immune responses and in the pathogenesis of arthritis 
as well as their idiotypic and epitopic specificities. 
Summary 
MRL/lpr/lpr (MRL/I)  mice  develop  a  lupus-like  syndrome  and  a  disease 
histologically and serologically similar to human rheumatoid arthritis. Their sera 
contain polyclonal IgM rheumatoid factors (RF) reactive with all  murine IgG 
subclasses (frequently strongest with IgG2a) and several heterologous IgG. To 
examine the repertoire and epitopic specificities of these RF, we fused splenocytes 
from 3.5-mo-old seropositive MRL/1 mice with appropriate myeloma partners 
and derived 1,723 hybridomas of which 23 secreted IgMRF. 
These monoclonal IgMRF bound to murine IgG only, not to other murine 
isotypes.  Eight  murine IgG  subclass-specific clonotypes were  identified.  Most 
clones reacted with either multiple IgG subclasses or with IgG2a alone. A few 
clones reacted  solely with  IgG2b but none reacted  exclusively with IgG1  or 
IgG3. Monoclonal IgMRF with exclusively anti-IgG2a activity exhibited allotypic 
specificity, reacting, with few exceptions, with a, c, and e, but not b, d, orj IgG2a 
allotypes. Four clonotypes could be distinguished by cross-reactivity with IgG 
from species other than  mice. Monoclonals possessing activity against several 
murine subclasses cross-reacted extensively with heterologous IgG, including all 
human IgG subclasses without allotypic restrictions. Monoclonal IgMRF specific 
for murine IgG2a or 2b did not cross-react with beterologous IgG. Based on the 
absence of cross-reactions by IgG2a-specific monoclonal autoantibodies, certain 
peptides of the IgG CH2  and CH3 domains appear to generate the antigenic 
determinants of the anti-IgG2a RF in MRL/I mice. 
All of the monoclonal RF bound to Fc and, with one exception, not to Fab 
fragments of murine IgG. Binding of the monoclonal RF to substrate IgG was 
not inhibited by Clq, thus excluding the Clq-binding site at the CH2 domain as 
one of the responsible epitopes in the induction of MRL/I RF. mIgMRF could 
be categorized as strongly, weakly, or noninhibitable by protein A, which inter- 
acts with IgG molecules at or near the CH2-CH3 junction. Inhibition appears to 
be caused by conformational changes and/or steric shielding of certain IgG areas 
distant from this junction and not by identical binding sites between protein A 
and RF.  Certain of the mlgMRF that were weakly or not at all inhibitable by 
protein A  were  found to  cross-react equally well with human Fc  (CH2-CH3 
domains) and pFc' (CH3 domain) fragments, indicating that the binding site for 
these monoclonals is at the CH3 domain. Monoclonal RF were devoid of anti- 916  MURINE  MONOCLONAL  IgM  RHEUMATOID  FACTORS 
double-strand DNA, anticoUagen, or antipeptidoglycan pentapeptide cross-reac- 
tivity, but one of the monoclonals cross-reacted with histones, four with single- 
strand DNA, and one with both histones and single-strand DNA. 
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